LYCOS RETRIEVER 
Do the Right Thing: Companies
built 177 days ago
The most impactful thing you can do is to seek out stories about companies doing (or not doing) the right thing that you find important, and share them with the world by posting them on the site. Every time you witness, read, or hear about information that is worth sharing, sprint to the nearest computer and post it for the world to see. Then, send the links to the stories you post and those posted by others that you find important to people who will ... find them important. As you spread dotherightthing, be sure to refrain from sending unsolicited mail to strangers and to be respectful and positive.
Source:
BETHESDA, MD. 06 June 2000 — The Department of Health and Human Services (HHS) plans to reduce Medicare’s expenses by relying on a new wholesale drug-pricing plan proposed by Medicaid, Secretary Donna E. Shalala informed the House committee investigating drug prices. In her letter last week to House Commerce Committee Chairman Tom Bliley (R-Va.), Shalala said that HHS will "take advantage of the newly available, more accurate data on average wholesale prices developed for Medicaid as a result of Department of Justice investigations." Both Medicaid, which pays for health care for the nation’s needy, and Medicare, which provides health insurance for the elderly, use published average wholesale prices (AWPs) in setting payment rates for outpatient drugs. Through the investigations, wrote Shalala, the Justice Department and state Medicaid fraud control units uncovered data about the wholesale prices for about 50 drugs. Those products account for about one third of Medicare’s drug expenses. The Justice Department forwarded the information to First DataBank Inc., the San Bruno, Calif.-based company that compiles the drug-pricing data used by state Medicaid programs to determine payment rates. . . . Shalala informed Bliley that HHS will provide Medicare carriers—the insurance companies contracted to pay claims for covered drugs—with the prices recently recalculated by First DataBank.
Source:
Given that many physicians are now dosing Norvir as a boosting agent, in reality what Abbot has done is price Norvir to generate the same dollar profit per 30 day prescription that they would have normally gotten per 120 capsule bottle. By their own statements regarding pricing, Kaletra, which has ritonivir, or Norvir, as one of it's ingredients, did NOT suffer a price increase. This would lead one to assume, given the company's further comments about the per dose pricing of Kaletra, that this is purely a marketing ploy to push for a larger market share for Kaletra, and ... to greatly profitize from the boosted regimens that Norvir is now a part of when coupled with drugs from other competing pharmaceutical companies. Abbott alleges that there was no price increase to ADAP or their 340b, public health pricing, or any other government funded purchasing. This indicates that there is no actual increase in production or manufacturing cost, but merely a profit move by Abbott who's cost will be paid by the consumer and the insurance companies. This is an outrage and a slap in the face to the HIV community as a whole.
Source:
Companies and their representatives and employees are only permitted to influence ratings by doing the right thing and sharing information about these activities with the dotherightthing community. If a company ever attempts to influence you to inflate its ratings, post that information and reveal evidence of this lapse in integrity to the rest of the world.
Source:
"We tried to convince Target that it should do the right thing and make its website accessible through negotiations," said Dr. Maurer. "It is unfortunate that Target took the position that it does not have to take the rights of the blind into account. The ruling in this case puts Target and other companies on notice that the blind cannot be treated like second class citizens on the Internet or in any other sphere."
Source:
[T]o get the maximum benefit, at least part of the training should be done in-person. An external vendor may be able to help facilitate the training, but it is most compelling if it comes from executives and other respected individuals within the organization. Taylor recommends finding volunteers within the company to serve as ethics champions. “Find extraordinary people other employees pay attention to,” he suggests, and ask them to be mentors that other employees can go to for advice on ethical dilemmas.
Source:
MORE ABOUT
Companies